Maintaining Investments in New Innovation Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Maintaining Investments in New Innovation Act
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 1672: Maintaining Investments in New Innovation Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1672/
"H.R. 1672: Maintaining Investments in New Innovation Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1672/.
H.R. 1672, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1672/.
[H.R. 1672: Maintaining Investments in New Innovation Act](https://openamerica.io/bill/119-HR-1672/)